MetaCap

Belite Bio (BLTE) vs Ligand Pharmaceuticals (LGND)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Ligand Pharmaceuticals (LGND) has outperformed Belite Bio (BLTE) over the past year, gaining 44.0% versus a gain of 5.7%. Ligand Pharmaceuticals is the larger company by market cap ($5.74 billion vs $5.17 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BLTE+5.66%LGND+43.98%
+66%+27%-12%
Nov 21, 20251 yearNov 20, 2026
BLTE+1102.83%LGND+395.18%
+1815%+856%-104%
Apr 25, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BLTE versus LGND key metrics
MetricBLTELGND
Share price$127.38$286.85
Market cap$5.17B$5.74B
1-day change-15.65%-0.03%
YTD return-20.37%+51.72%
1-year return+5.66%+43.98%
5-year return—+193.16%
P/E ratio (TTM)—115.20
Forward P/E—24.00
EPS (TTM)$-2.84$2.49
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$268.09M
Revenue growth (YoY)—+60.40%
Net income (latest FY)$-77.61M$124.45M
Operating margin—15.29%
Net margin—46.42%
52-week high$200.00$326.63
52-week low$115.41$175.89
Distance from 52-week high-36.31%-12.18%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+82.92%+25.94%
Average volume195.65K230.79K
Shares outstanding40.61M20.00M
Employees4147
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • LGND has outperformed BLTE by 38.3 percentage points over the past year.

About Belite Bio

BLTE stock →

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.

Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees

About Ligand Pharmaceuticals

LGND stock →

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 47 employees

BLTE vs LGND FAQ

Which is bigger, Belite Bio or Ligand Pharmaceuticals?

Ligand Pharmaceuticals (LGND) is larger, with a market capitalization of $5.74B compared with $5.17B for Belite Bio (BLTE).

Which stock has performed better over the past year, BLTE or LGND?

LGND returned +43.98% over the past 12 months, compared with +5.66% for BLTE (price return, excluding dividends). Past performance does not predict future results.

Are Belite Bio and Ligand Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons